JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2014, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2014-05-06
DOI
10.1155/2014/283617
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
- (2013) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- Jakpot! New small molecules in autoimmune and inflammatory diseases
- (2013) Kamran Ghoreschi et al. EXPERIMENTAL DERMATOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Tofacitinib
- (2013) Drugs in research & development
- Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography
- (2012) April W. Armstrong et al. AMERICAN JOURNAL OF CARDIOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
- (2012) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
- (2012) Mamoudou Maiga et al. JOURNAL OF INFECTIOUS DISEASES
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis
- (2012) David A. Fox NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
- (2011) Jordan S. Fridman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Signal transduction pathways and transcriptional regulation in Th17 cell differentiation
- (2010) Kiyoshi Hirahara et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
- (2009) B. Y. Chang et al. JOURNAL OF IMMUNOLOGY
- IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells
- (2009) W. A. Goodman et al. JOURNAL OF IMMUNOLOGY
- Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
- (2009) Mary G. Boy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Th17 cells: a new fate for differentiating helper T cells
- (2008) Zhi Chen et al. IMMUNOLOGIC RESEARCH
- Therapeutic targeting of Janus kinases
- (2008) Marko Pesu et al. IMMUNOLOGICAL REVIEWS
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004
- (2008) Shanu Kohli Kurd et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More